WuXi AppTec is partnering with Qiagen to develop biomarkers, assay panels and personalised healthcare diagnostics and will use these, and existing technologies, to further clients’ projects.
Dutch sample and assay technology expert Qiagen has continued its march into the detection system market with the acquisition of Biotage’s Biosystems business.
Dutch assay experts Qiagen are aiming to remove the bottlenecks
hindering important research into the epigenetics of cancer and
hereditary diseases with the expansion of its EpiTect product line.
LabTechnologist.com brings you its periodic round up of industry
news, featuring developments at Affymetrix, Mettler-Toledo,
Fluidigm, Oxford Instruments, Qiagen and TTP Labtech.
LabTechnologist.com brings you its periodic round up of industry
news, with Qiagen agreeing to buy Digene, Roche Diagnostics
settling a tax evasion investigation and agreements between Bio-Rad
and Beckman Coulter, Waters and Rosetta...
Germany's Capsulution Nanoscience is tapping into Qiagen's
molecular diagnostics expertise in a collaboration that will
explore new diagnostic and therapeutic possibilities for cancer and
other diseases.
Qiagen, today announced that it has acquired all outstanding shares
of Genaco Biomedical Products in a deal that adds PCR-based,
multiplexed molecular diagnostics technologies and panels to
Qiagen's portfolio.
Dutch nucleic acid specialist, Qiagen, has entered into an
agreement to acquire Nextal Biotechnology, a provider of sample
preparation tools which make protein crystallisation more
accessible. The deal also signals Qiagen's intention...
Qiagen has acquired the PCR diagnostics company Artus, in a move
that now allows Qiagen to offer preanalytical sample preparation
and diagnostic assay solutions to its partners in molecular
diagnostics. The acquisition further allows...
Qiagen has released two protein purification kits that provide
affordable automation as a way to increase throughput and free up
valuable manpower for less routine tasks.
Qiagen and Procognia have entered into a marketing and licensing
agreement, which targets the emerging field of protein
glycoanalysis. The combination of Qproteome products with
Procognia's On-Chip Glycoanalysis technology aims...
Qiagen has announced the acquisition of RNAture's nucleic acid
isolation products from Hitachi Chemical Research Centre. The
latest acquisition sees Qiagen purchase an extensive range of
products that addresses high-throughput...
Qiagen has launched the world's first automated sample preparation
system for viral nucleic acids to aid molecular diagnostics that
conforms to a European Union Directive on in vitro diagnostic
medical devices.
Netherlands-based Qiagen achieved organic growth of 32 per cent for
the second quarter of 2004, but profits fell by a fifth as the cost
of restructuring took its toll.
Qiagen has sold off its embattled nucleic acid synthesis business
in a management buyout, but has retained a minority stake and all
activities relating to RNA interference (RNAi), a potent new drug
discovery tool.
Qiagen and Protedyne have teamed up to develop an ultra
high-throughput sample preparation system for Protedyne's BioCube
systems used for nucleic acid purification,writes Wai Lang
Chu.
Dutch nucleic acid specialist Qiagen reported strong growth in
sales in the first quarter of 2004, ahead of its forecasts, as
spending by companies in the pharmaceutical industry returns to
historical levels, writes Wai Lang Chu.
Nucleic acid specialist Qiagen has reported a strong growth in
sales and profits for the fourth quarter of 2003, providing another
indication that the pharmaceutical and biotechnology industry's
investment in R&D may be recovering.
Qiagen of the Netherlands has started shipping a set of RNA
interference (RNAi) reagents that correspond to the 5,000 or so
genes in the human genome thought most likely to be viable targets
for drug discovery.
Qiagen has reported strong growth in sales and profits in the
second quarter as last year's acquisitions of GenoVision and
Xeragon start to exert their effects. The company has also signed
two new deals in the area of RNA interference.
